Gilead's HIV drug wins FDA approval to treat hepatitis B

08/11/2008 | Forbes

The FDA cleared Viread, an HIV medication from Gilead Sciences, to treat hepatitis B. The expanded approval was based on two clinical studies showing that the drug outperformed Hepsera -- Gilead's hepatitis B treatment -- in fighting liver inflammation and scarring. The decision came on the same day that a federal appeals court in San Francisco reinstated a lawsuit from shareholders over Gilead's alleged marketing of Viread for off-label applications.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ